drugset
drugset / Trial / NCT06471673

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

NCT06471673 ↗

Phase 1/2 Recruiting 18 enrolled BriaCell Therapeutics Corporation
Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open-label Phase 1/2a study. Once the safety of the BC1 cell line alone has been demonstrated in Phase 1, in Phase 2, patients will be treated with the Bria-OTS regimen (see below) and a clinically available check point inhibitor (CPI). During the monotherapy phase of Phase 1, one patient will be treated intradermally every 2 weeks for 6 weeks (4 doses) with an initial dose of the BC1 cell line. If this dose is tolerated, the next patient will receive an increased dose of BC1. If once again tolerated, the third patient will receive a further dose increase of the BC1. Once at least 3 patients have been safely treated with the BC1 cell line, with no dose-limiting toxicity (DLT), the combinational phase of the study will commence. Following the monotherapy phase, patients will be treated with BC1 and the Bria-OTS regimen (see below) every 3 weeks, plus a CPI at the FDA approved labelled dose and schedule. There will be at least a 2-week spacing between enrollment of each of the first three subjects in the study in order to assess for any early unanticipated risk(s). During the Phase 1 combination and Phase 2 expansion phases, all patients will be treated with BC1 cells as part of the Bria-OTS regimen, which includes cyclophosphamide 300 mg/m2 2-3 days prior to BC1 cell inoculation, and peginterferon alpha-2a administered on the same day, following BC1 cell inoculation.

Timeline

Start
2024-05-29
Primary completion
2025-04-30
Completion
2025-10-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject BC1 cell line Cell therapy 1e+07 cells Intrathecal
Background Cyclophosphamide Other / unclassified 300 mg/m2 —
Background Peginterferon alfa-2a Protein / enzyme biologic — —
Background Tislelizumab Monoclonal antibody — —

Indications

breast cancer